GRI BIO, Inc. Files S-1 for Security Registration

Ticker: GRI · Form: S-1 · Filed: Jun 20, 2024 · CIK: 1824293

Gri Bio, INC. S-1 Filing Summary
FieldDetail
CompanyGri Bio, INC. (GRI)
Form TypeS-1
Filed DateJun 20, 2024
Risk Levelmedium
Pages16
Reading Time19 min
Key Dollar Amounts$0.0001, $0.125, $0, $2.861, $10.0 million
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, s-1, pharmaceuticals, registration

TL;DR

GRI BIO (fka Vallon Pharma) filed S-1, get ready for new shares.

AI Summary

GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an S-1 form on June 20, 2024, to register securities. The company, incorporated in Delaware with its principal office in La Jolla, California, operates in the Pharmaceutical Preparations sector. GRI BIO, Inc. previously operated under the name Vallon Pharmaceuticals, Inc. until a name change on September 10, 2020.

Why It Matters

This S-1 filing indicates GRI BIO, Inc. is preparing to offer securities to the public, which could lead to new funding and increased trading activity.

Risk Assessment

Risk Level: medium — S-1 filings are typically for companies seeking to raise capital through public offerings, which inherently carry market and execution risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1 filing?

The S-1 filing is a registration statement filed with the SEC for the registration of securities, indicating GRI BIO, Inc.'s intent to offer them to the public.

When was GRI BIO, Inc. formerly known as?

GRI BIO, Inc. was formerly known as Vallon Pharmaceuticals, Inc., with a name change occurring on September 10, 2020.

Where is GRI BIO, Inc. located?

GRI BIO, Inc.'s business and mailing address is 2223 Avenida De La Playa, Suite 208, La Jolla, CA 92037.

What industry does GRI BIO, Inc. operate in?

GRI BIO, Inc. operates in the Pharmaceutical Preparations sector, identified by the Standard Industrial Classification code 2834.

What is the SEC file number associated with this filing?

The SEC file number for this S-1 filing by GRI BIO, Inc. is 333-280323.

Filing Stats: 4,749 words · 19 min read · ~16 pages · Grade level 14.6 · Accepted 2024-06-18 19:51:32

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 13 Cautionary Note Regarding Forward-Looking Statements 56

Use of Proceeds

Use of Proceeds 58 Market Information 59 Dividend Policy 60 Capitalization 61

Management's Discussion And Analysis of Financial Condition and Results of Operations

Management's Discussion And Analysis of Financial Condition and Results of Operations 65

Business

Business 76 Management 115 Executive And Director Compensation 122 Certain Relationships And Related Party Transactions 129

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 131

Description of Capital Stock

Description of Capital Stock 133

Description of Securities We Are Offering

Description of Securities We Are Offering 139 Material U.S. Federal Income Tax Consequences to Holders of Common Stock and Warrants 143 Plan of Distribution 150 Legal Matters 154 Experts 154 Where You Can Find More Information 154 Index to Consolidated Financial Statements F- 1 You should rely only on the information contained in this prospectus. No one, including but not limited to the Placement Agent, has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date. i ABOUT THIS PROSPECTUS Unless the context otherwise requires or as otherwise noted, we use the terms "GRI," "Company," "we," "us" and "our" in this prospectus to refer to GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc.) and its subsidiaries taken as a whole. We have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing